Sentences with phrase «treatments than patients»

Past research has shown that caregivers place a much higher emphasis on life extension and are willing to pay greater amounts for moderately life extending treatments than patients.

Patients who were offered pharmacotherapy alone were 1.76 times more likely to refuse treatment than patients who were offered psychotherapy alone.

Genotyping of a population of 329 patients with early RA revealed just over one - quarter had the allele * 2 HS1, 2 A enhancer, and one in 10 the allele * 1 HS1, 2 A enhancer, which is comparable with previously published data.7 Patients with the allele * 2 genotype had more active disease at the start of treatment and were significantly less likely to achieve a good response and / or remission after three months treatment than those patients with the allele * 1 genotype.

Not exact matches

Telemedicine services, such as Teladoc, can streamline the treatment process because it connects patients remotely to certified physicians around the US, via phone, video - conferencing, and online, rather than relying on local access to physicians.

But now that Obamacare is ensuring health care providers get paid for better outcomes rather than the number of visits a patient makes to the doctor, you can be sure hospitals will be using data to make sure they're delivering the best treatment they can.

When patients receive more treatment than deemed necessary for their situation, some or all of the extra costs will often come out of the providers» pockets, instead of generating more income.

At one eating - disorder treatment clinic in New York City, more than half the patients report having tried a juice cleanse, Marie Claire reports.

«More than twice the number of patients [were] still living at the end of the study after receiving IMAB362 plus chemotherapy compared to chemotherapy alone,» according to Ganymed CEO Özlem Türeci, with patients showing the highest level of that protein biomarker responding best to the treatment.

But the study also suggested that some antidepressants were more effective than others; several older antidepressants were found to be more effectivee than more modern ones, but the modern treatments (such as Prozac) were better tolerated by patients.

And he built on that concept on Thursday, announcing that his firm will bolster its patient assistance programs for more than 40 drugs, including by helping people who make up to four times the federal poverty level buy their treatments for free.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since massive Hurricane Maria struck in September and knocked out the dialysis center on the tiny satellite island of Vieques, more than a dozen patients needing treatment now must fly several times a week to the main island.

REINVENTING THE CLINICAL TRIAL Research Track Traditional clinical trials ask one question: Does an experimental treatment work better than nothing at all — or, the very least, the standard therapy offered patients.

The trial doesn't have a control group, but that seem's much longer than patients who relapse after treatment with Jakafi.

Although it's not contagious and the number of half monkeys having such illness is quite immaterial than alarming, yet the patient revealing such symptoms must be brought to the nearest vet for immediate treatment.

A disturbing article published in JAMA Internal Medicine propounded a «worse than death» category to measure patient suffering in the context of making treatment decisions for hospitalized patients.

Tranquilizing drugs play the major role, drastically reducing the need for physical restraints, rendering many patients amenable to treatment, and often allowing them to leave the hospital much sooner than would otherwise be feasible.

The most shocking fact revealed by the Joint Commission's report was that «More than half of the patients in most State hospitals receive no active treatment.»

Rather than the common policy of discharging such patients to nursing homes when family members insist on continued treatment or the insurance money runs out, Catholic institutions could develop sorely needed long «term rehabilitation facilities that could build on the encouraging work being done with such patients in England and Israel.

i'm glad that you're finding time during D3 to do fun things other than stress about treatment for your new patients.

With that being said, not everyone reacts the same to treatments and procedures, so it is entirely possible that your body might react differently than another patient.

However, parents and patients really need to understand that there is no proof that PRP will prevent surgery, relieve their symptoms, or be better than standard treatment options.

We have offices across the state, giving more patients access to the latest innovations and treatment options than ever before.

About Memorial Sloan - Kettering Cancer Center: The world's oldest and largest private cancer center, Memorial Sloan - Kettering Cancer Center (MSKCC) has devoted more than a century to patient care as well as to innovative research, making significant contributions to new and better therapies for the treatment of cancer.

Patients who underwent timed intrauterine insemination after the Cap - Score Test had a higher chance of pregnancy than under other treatment regimens for unexplained infertility.

This is why cancer patients using alternative diet treatments as an adjunct to medicinal care often do * worse * than cancer patients who stick to just medical care.

In its latest «care guarantee,» Sweden found it necessary to stipulate that patients must be able to see a doctor within seven days; patients should not wait more than 90 days to see a specialist; and treatment should be scheduled within 90 days... six months from presentation;

Tony Blair committed today to «transform» the way health services are delivered, pledging that no patient will wait more than 18 weeks for NHS treatment by the end of 2008.

He said he'd rather put his faith in the F.D.A. or the Memorial Sloan - Kettering Cancer Center, where he receives treatment, than the state health department when it comes to determining if medical marijuana will actually benefit cancer patients.

Stage two was to widen diversity of supply to create new incentives for better local performance and more choice for patients - a success story in achieving the shortest ever waiting times including meeting our commitment to less than eighteen weeks from doctor's appointment to hospital treatment, and improving the management of NHS resources through foundation hospitals and the use of the private sector.

It has been revealed that over 10,000 patients have been waiting for more than 36 weeks until the start of their NHS treatment; an increase of around 1,195 compared to the previous month.

Twenty patients with kidney failure, for example, showed levels of ammonia and acetone more than 10 times that of healthy controls, and the researchers could watch those levels fall back to normal as the patients received dialysis treatment.

Despite complications sometimes more severe than with standard radiation therapy — and costs that are much higher for taxpayers, patients and insurers — proton beam therapy is heavily marketed for treatment of prostate cancer.

Partly because of a marketing push, prostate cancer patients have flocked to proton therapy despite the lack of evidence that it's better than less expensive treatment.

More than twice as many people in EAET (34.8 percent) reported that they were «much better» or «very much better» than before treatment, compared to 15.4 percent of education patients.

One of the studies, published in 2008, suggested that patients whose antiretroviral treatment was deferred until their CD4 cell counts were below 250 were at greater risk of opportunistic infection than those that received antiretroviral treatment when CD4 cell counts were higher than 350.

Active surveillance involves regular testing to check for cancer growth rather than immediate treatment, and many patients with low - risk prostate cancer on active surveillance may be able to avoid treatment for several years or altogether.

The study also suggests that targeting the machinery that makes cells mobile, rather than targeting the tissue - clearing process — which has been tested in patients but has not been very effective — may be a better treatment strategy to stop cancers from spreading.

Since its inception in 2012, patient enrollment in treatment trials at CTCA at Western has increased by more than 800 percent.

No major toxic effects were observed, and the patient «was able to survive a much longer period than expected with an improved quality of life, which is clearly attributable to the treatment with 3BP,» the scientists concluded.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet.

Depressed men with localized prostate cancer were more likely to be diagnosed with more aggressive prostate cancer, received less effective treatments and survived for shorter times than prostate cancer patients who were not depressed, a UCLA study has found.

Among patients not given a choice, treatment with prolonged exposure psychotherapy cost less on than sertraline.

Among the patients not given a choice of treatment, counseling with prolonged exposure therapy cost on average slightly less than pharmacotherapy with sertraline — $ 7,030 versus $ 8,650 per patient per year.

Cancer researchers have long observed the value of treating patients with combinations of anti-cancer drugs that work better than single drug treatments.

«We urgently need new treatments for lung cancer patients, and this research suggests we can boost the effectiveness of an existing drug, rather than switch to another new expensive treatment.

Finding new treatments is critical because less than 5 percent of patients with pancreatic neuroendocrine tumors respond to everolimus, the most commonly used pharmaceutical, François said.

«We found genetic alterations in brain metastases that could affect treatment decisions in more than half of the patients in our study,» Dr Brastianos will say.

«Incidence of cancer in patients with large colorectal polyps lower than previously thought: 92 percent of the colorectal polyps in patients referred for operations were noncancerous, suggesting advanced endoscopic treatments may be a viable option.»